EP1180140A4 - Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway - Google Patents

Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway

Info

Publication number
EP1180140A4
EP1180140A4 EP00920190A EP00920190A EP1180140A4 EP 1180140 A4 EP1180140 A4 EP 1180140A4 EP 00920190 A EP00920190 A EP 00920190A EP 00920190 A EP00920190 A EP 00920190A EP 1180140 A4 EP1180140 A4 EP 1180140A4
Authority
EP
European Patent Office
Prior art keywords
traf2
tnf
variants
inhibitor
act
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00920190A
Other languages
German (de)
French (fr)
Other versions
EP1180140A1 (en
Inventor
George H Searfoss Iii
Marco F Pagnoni
Yuri D Ivashchenko
Kun Guo
Kenneth L Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gencell SAS
Original Assignee
Gencell SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencell SAS filed Critical Gencell SAS
Publication of EP1180140A1 publication Critical patent/EP1180140A1/en
Publication of EP1180140A4 publication Critical patent/EP1180140A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
EP00920190A 1999-04-30 2000-04-06 Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway Withdrawn EP1180140A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13194099P 1999-04-30 1999-04-30
US131940P 1999-04-30
PCT/US2000/009178 WO2000066737A1 (en) 1999-04-30 2000-04-06 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY

Publications (2)

Publication Number Publication Date
EP1180140A1 EP1180140A1 (en) 2002-02-20
EP1180140A4 true EP1180140A4 (en) 2004-08-25

Family

ID=22451697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00920190A Withdrawn EP1180140A4 (en) 1999-04-30 2000-04-06 Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway

Country Status (10)

Country Link
EP (1) EP1180140A4 (en)
JP (1) JP2002542826A (en)
KR (1) KR20020012194A (en)
CN (1) CN1309830C (en)
AU (2) AU4076800A (en)
CA (1) CA2372803A1 (en)
HU (1) HUP0200946A3 (en)
IL (1) IL146241A0 (en)
MX (1) MXPA01011107A (en)
WO (1) WO2000066737A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003458D0 (en) * 2000-02-16 2000-04-05 Secr Defence Brit Rubber structure & method of making the same
CA2449487A1 (en) * 2001-06-07 2002-12-12 Pu Xia Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
US20050180974A1 (en) * 2003-10-24 2005-08-18 Medtronic, Inc. Extracellular TNF inhibitors for treating CNS disorders
WO2022152856A1 (en) * 2021-01-15 2022-07-21 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Methods and compositions for treating ischaemia in a subject
CN114672550B (en) * 2022-05-05 2023-11-17 青岛大学 Atherosclerosis biomarker and inhibitor and application thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAO Z ET AL: "TRAF6 IS A SIGNAL TRANSDUCER FOR INTERLEUKIN-1", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 383, October 1996 (1996-10-01), pages 443 - 446, XP002926064, ISSN: 0028-0836 *
DADGOSTAR HAJIR ET AL: "An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 38, 18 September 1998 (1998-09-18), pages 24775 - 24780, XP002278075, ISSN: 0021-9258 *
DUCKETT COLIN S ET AL: "Induction of nuclear factor kappa-B by the CD30 receptor is mediated by TRAF1 and TRAF2", MOLECULAR AND CELLULAR BIOLOGY, vol. 17, no. 3, 1997, pages 1535 - 1542, XP002278074, ISSN: 0270-7306 *
HORIE RYOUICHI ET AL: "A novel domain in the CD30 cytoplasmic tail mediates NFkB activation", INTERNATIONAL IMMUNOLOGY, vol. 10, no. 2, February 1998 (1998-02-01), pages 203 - 210, XP002278073, ISSN: 0953-8178 *
HSU H ET AL: "TRADD-TRAF2 AND TRADD-FADD INTERACTIONS DEFINE TWO DISTINCT TNF RECEPTOR 1 SIGNAL TRANSDUCTION PATHWAYS", CELL, MIT PRESS, CAMBRIDGE, MA,, US, vol. 84, no. 2, 26 January 1996 (1996-01-26), pages 299 - 308, XP000607990, ISSN: 0092-8674 *
LEE SOO YOUNG ET AL: "CD30/TNF receptor-associated factor interaction: NF-kappa-B activation and binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 18, 1996, 1996, pages 9699 - 9703, XP002278072, ISSN: 0027-8424 *
ROTHE M ET AL: "A NOVEL FAMILY OF PUTATIVE SIGNAL TRANSDUCERS ASSOCIATED WITH THE CYTOPLASMIC DOMAIN OF THE 75 KDA TUMOR NECROSIS FACTOR RECEPTOR", CELL, MIT PRESS, CAMBRIDGE, MA,, US, vol. 78, no. 4, 26 August 1994 (1994-08-26), pages 681 - 692, XP000607783, ISSN: 0092-8674 *
ROTHE M ET AL: "TRAF2-MEDIATED ACTIVATION OF NF-KB BY TNF RECEPTOR 2 AND CD40", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 269, no. 5229, 8 September 1995 (1995-09-08), pages 1424 - 1427, XP000608733, ISSN: 0036-8075 *
See also references of WO0066737A1 *

Also Published As

Publication number Publication date
CA2372803A1 (en) 2000-11-09
HUP0200946A3 (en) 2005-06-28
AU4076800A (en) 2000-11-17
IL146241A0 (en) 2002-07-25
WO2000066737A1 (en) 2000-11-09
JP2002542826A (en) 2002-12-17
AU2005203749A1 (en) 2005-09-15
EP1180140A1 (en) 2002-02-20
KR20020012194A (en) 2002-02-15
CN1309830C (en) 2007-04-11
HUP0200946A2 (en) 2002-07-29
CN1353754A (en) 2002-06-12
MXPA01011107A (en) 2002-08-09
WO2000066737A9 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
EP1406875A4 (en) N-heterocyclic inhibitors of tnf-alpha expression
IL145778A0 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
IL149118A0 (en) Inhibitors of neuraminidases
AU3408801A (en) Tnf-alpha inhibitors
EP1165084A4 (en) Inhibitors of prenyl-protein transferases
AU2001234088A1 (en) TNF-alpha inhibitors
EP1494699A4 (en) Methods for inhibiting vascular hyperpermeability
AU2003225088A8 (en) Regulation of tnf-alpha
AU5981101A (en) Method for the prevention of apoptosis
HUP0201846A2 (en) Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
GB9930659D0 (en) Inhibitors of complement activation
AU5969101A (en) Modulators of tnf-alpha signaling
GB0202254D0 (en) Prevention of scarring
GB9923866D0 (en) Correlation of signalling messages
IL145772A0 (en) Prodrugs of thrombin inhibitors
EP1158982A4 (en) Inhibitors of prenyl-protein transferase
EP1180140A4 (en) Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway
AU2001232245A1 (en) Tnf- alpha inhibitors
EP1221963A4 (en) Methods of inhibiting osteoclastogenesis
EP1409463A4 (en) N-heterocyclic inhibitors of tnf-alpha expression
EP1165013A4 (en) Inhibitors of prenyl-protein transferase
AU2003299137A8 (en) Inhibition of metallo-beta-lactamase
AU2003300551A8 (en) Compounds for the inhibition of non-proteolytic enzymes
AU2003271988A8 (en) Modulation of tgfbeta-like signalling pathways
EP1158983A4 (en) Inhibitors of prenyl-protein transferase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20011127

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENCELL S.A.

A4 Supplementary search report drawn up and despatched

Effective date: 20040712

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/12 A

17Q First examination report despatched

Effective date: 20041007

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENTELION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080419